Letter to the editor submitted in response to ‘Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study’

"Letter to the editor submitted in response to ‘Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study’." Journal of Dermatological Treatment, 33(7), pp. 3066–3067

Author contributions

Napolitano Maddalena: conceptualization, validation, visualization, writing-original draft preparation, writing – review and editing. Potestio Luca: data curation, formal analysis, investigation, visualization, writing – original draft preparation, writing – review and editing. Di Vico Francesca: data curation, investigation, methodology, visualization, writing – original draft preparation. Fabbrocini Gabriella: conceptualization, validation, visualization, writing – review and editing, supervision. Patruno Cataldo: conceptualization, validation, visualization, writing-original draft preparation, writing – review and editing.

All authors read and approved the final version of the manuscript.

Disclosure statement

M.N. acted as speaker, consultant and/or advisory board member for Abbvie, Eli Lilly, Leo Pharma, Novartis, and Sanofi. G.F. has been principal investigator in clinical trials sponsored by and/or and has received personal fees from AbbVie, Abiogen, Almirall, Celgene, Eli-Lilly, Leo Pharma, Novartis, Sanofi, and UCB. C.P. acted as investigator, speaker, consultant, and/or advisory board member for AbbVie, Amgen, Eli Lilly, Leo Pharma, Novartis, Pfizer, Pierre Fabre, and Sanofi. The remaining authors report no conflicts of interest.

Data availability statement

Data that support the findings of this study are available from the corresponding author, M.N., upon reasonable request.